Stratvocate offers a wealth of information and easy-to-use tools for those involved in federal contracting.

Subject: IR System Add-ons (Microplastics)
Solicitation Number: NOI-FDA-134639
Notice Type: PRESOL
NAICS: 334516
Set-Aside: No Set aside used
Notice Published: 07-30-26
Response Due: 08-13-26

Agency: Department of Health and Human Services
Office: FOOD AND DRUG ADMINISTRATION
Contact: Aarati Singal This email address is being protected from spambots. You need JavaScript enabled to view it.
Office Address: Rockville, MD 20852
Place of Performance: College Park, MD 20740


Click for official SAM (FBO) notice, additional information, and accompanying attachments

Pursuant to RFO 5.101(c)(4)(vii), the following identifies the intended source and explains why competition is not practicable for this requirement. Intended Contractor: Photothermal Spectroscopy Corp. 325 Chapala St Santa Barbara, CA 93101 CAGE Code: 83PQ8 The basis for limiting this solicitation to a single source is that only one source is reasonably available, consistent with RFO 13.101(b) and the single-source standard at RFO 12.201-1(c). Photothermal Spectroscopy Corp??PSC? is the one and only?supplier that can meet the performance requirements?outlined in the?Statement of?Work.?The?counter-propagating mode upgrade?must be 100% compatible with the existing?Photothermal?mIRageLS?to provide a seamless integration and?establish?full?system communication?and control?through?the?single, existing?software currently at FDA.?PSC owns the patent for intellectual property protecting the O-PTIR technology and its associated capabilities. O-PTIR is protected by multiple patents and is exclusively available from Photothermal Spectroscopy. PSC will be the only provider to support the FDA in this requirement of the necessary parts and knowledgeable installation team to ensure?100% compatibility?of?the upgrade?with?the current FDA instrument.?Photothermal is a US company?and is a registered small business.?A Brand Name?acquisition is recommended, since only one provider meets the requirements for the acquisition.? A written single-source justification has been prepared and approved in accordance with RFO 12.201-1(c) and RFO 13.101(b).